Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells

FLT3 activating mutations are the most frequent single genetic abnormality in patients with acute myeloid leukemia. Thus targeting the FLT3 activated kinase is a promising treatment approach. We wanted to test whether the protein tyrosine kinase inhibitor SU5614 selectively eliminates leukemic stem...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haematologica (Roma) 2005-11, Vol.90 (11), p.1577-1578
Hauptverfasser:	Arseni, N, Ahmed, F, Hiddemann, W, Buske, C, Feuring-Buske, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Cells, Cultured fms-Like Tyrosine Kinase 3 - genetics Hematopoietic Stem Cells - drug effects Hematopoietic Stem Cells - enzymology Humans Indoles - pharmacology Indoles - therapeutic use Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - enzymology Leukemia, Myeloid, Acute - genetics Middle Aged Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FLT3 activating mutations are the most frequent single genetic abnormality in patients with acute myeloid leukemia. Thus targeting the FLT3 activated kinase is a promising treatment approach. We wanted to test whether the protein tyrosine kinase inhibitor SU5614 selectively eliminates leukemic stem cells while sparing their normal counterparts.
ISSN:	0390-6078 1592-8721